Corcept Therapeutics Faces Legal Investigation After FDA Response
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Should l Buy CORT?
Source: Globenewswire
Corcept Therapeutics Inc (CORT) shares are up 11.54% in pre-market trading, reaching a 5-day high, despite facing significant challenges following the FDA's complete response letter regarding its drug relacorilant.
The FDA's response, issued on December 31, 2025, has led to a drastic decline in investor confidence, with shares plummeting 50% previously. The agency's request for additional evidence of effectiveness has raised concerns about relacorilant's market viability, prompting investigations into potential securities fraud by law firms like Pomerantz LLP and Hagens Berman. This legal scrutiny may further impact the company's reputation and investor trust.
Despite the current price increase, the long-term implications for Corcept remain uncertain as it navigates these legal challenges and the FDA's stringent requirements for relacorilant.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 33.540
Low
50.00
Averages
91.00
High
121.00
Current: 33.540
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson Fistel Investigates Claims for Corcept Investors
- FDA Response Impact: On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter for its new drug application, causing a 50% drop in share price, highlighting the direct impact of regulatory approvals on the company's financial health.
- Market Reaction Intensifies Losses: On January 30, 2026, the market reacted strongly to a corrected CRL, indicating that the FDA had previously raised concerns about the adequacy of the clinical development program, leading to another significant decline in share price, reflecting a crisis of trust among investors regarding company transparency.
- Legal Investigation Initiated: Johnson Fistel is investigating whether Corcept complied with federal securities laws, and if violations are found, it may recover losses for investors, underscoring the importance of legal action in protecting investor rights.
- Investor Rights Protection: Johnson Fistel, a nationally recognized shareholder rights law firm, has recovered approximately $90.725 million for clients, emphasizing its effectiveness in securities litigation and commitment to investor advocacy.
See More
Corcept's Drug Application Rejected by FDA, Class Action Filed
- FDA Rejection: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter (CRL) declining to approve its New Drug Application (NDA) for relacorilant, citing insufficient evidence of effectiveness, which led to a 50.42% drop in stock price to $34.80, highlighting significant regulatory risks impacting the company's valuation.
- Stock Price Volatility: Following the FDA's rejection, Corcept's stock plummeted by $35.40, reflecting a pessimistic market sentiment regarding the company's future prospects and severely undermining investor confidence in its drug development capabilities, potentially affecting future financing and R&D initiatives.
- Class Action Initiated: Investors have filed a class action lawsuit due to purchasing Corcept stock between October 31, 2024, and December 30, 2025, alleging that the company made misleading statements and failed to disclose FDA concerns about its clinical development program, which may expose investors to greater losses.
- Legal Implications: Investors must file their motions by April 21, 2026, to be appointed as lead plaintiffs in the class action, indicating that the legal risks faced by the company could further damage its market reputation and shareholder trust, increasing future compliance costs.
See More
Corcept Therapeutics Faces Class Action Lawsuit Over Misleading Statements
- Lawsuit Background: Hagens Berman has filed a class action lawsuit against Corcept Therapeutics and its executives, alleging that they misled investors about the regulatory status of relacorilant, resulting in significant investor losses during the period from October 31, 2024, to December 30, 2025.
- Concealed FDA Warnings: The lawsuit claims that while Corcept publicly asserted that relacorilant was approaching approval, the FDA had warned them multiple times that their clinical data was inadequate, which management allegedly chose to ignore.
- Stock Price Plummet: On December 31, 2025, Corcept's stock price collapsed from $70.20 to $34.80 following the receipt of a Complete Response Letter (CRL) from the FDA, erasing over $3.6 billion in market value and severely impacting investor confidence.
- Legal Consequences and Deadline: Investors must apply to be lead plaintiffs by April 21, 2026, or risk losing their opportunity for recovery, highlighting the potential long-term implications of the lawsuit on the company's future.
See More
Corcept Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications for the Corcept securities class action by April 21, 2026, concerning trades made between October 31, 2024, and December 30, 2025, highlighting investor concerns over potential losses.
- Disclosure Failures: Corcept and its executives are accused of failing to disclose material information during the class period, violating federal securities laws, which severely undermined investor confidence in the company's new drug application.
- Stock Price Plunge: Following the December 31, 2025 disclosure of the FDA's Complete Response Letter regarding its new drug application, Corcept's stock price plummeted by 50.4%, from $70.20 to $34.80, indicating a pessimistic outlook from the market on the company's future prospects.
- Legal Consultation Opportunity: Investors can contact Kahn Swick & Foti to understand their legal rights and how to participate in the lawsuit, reflecting a strong demand among investors for recovering economic losses.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation among affected investors.
- Case Background: The lawsuit alleges that Corcept made false statements regarding the clinical trials supporting the NDA for relacorilant, claiming that the evidence was “powerful support,” while the FDA had raised concerns about its adequacy, resulting in significant investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Navan and Corcept Face Class Action Lawsuits
- Navan IPO Issues: Navan conducted its IPO on October 30, 2025, selling approximately 36.9 million shares at $25 each, but due to undisclosed increases in sales and marketing expenses, its stock plummeted to $9.01 by the time the lawsuit commenced, representing a decline of over 60%, resulting in significant investor losses.
- Lawsuit Deadlines: Navan shareholders must petition to serve as lead plaintiff by April 24, 2026, reflecting investor concerns over the company's transparency and financial health, which could impact future fundraising capabilities.
- Corcept Approval Risks: Corcept's relacorilant faced a Complete Response Letter from the FDA on December 31, 2025, requiring additional evidence of effectiveness, causing its stock price to drop from $70.20 to $34.80, a 50.4% decline, highlighting significant uncertainties in the company's drug development.
- FDA Communication Missteps: During the class period, Corcept claimed smooth communication with the FDA and confidence in its NDA submission, but the FDA's concerns about clinical evidence raised the risk of non-approval, exacerbating investor confidence issues.
See More
Johnson Fistel Investigates Claims for Corcept Investors
- FDA Response Impact: On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter for its new drug application, causing a 50% drop in share price, highlighting the direct impact of regulatory approvals on the company's financial health.
- Market Reaction Intensifies Losses: On January 30, 2026, the market reacted strongly to a corrected CRL, indicating that the FDA had previously raised concerns about the adequacy of the clinical development program, leading to another significant decline in share price, reflecting a crisis of trust among investors regarding company transparency.
- Legal Investigation Initiated: Johnson Fistel is investigating whether Corcept complied with federal securities laws, and if violations are found, it may recover losses for investors, underscoring the importance of legal action in protecting investor rights.
- Investor Rights Protection: Johnson Fistel, a nationally recognized shareholder rights law firm, has recovered approximately $90.725 million for clients, emphasizing its effectiveness in securities litigation and commitment to investor advocacy.
See More
Corcept's Drug Application Rejected by FDA, Class Action Filed
- FDA Rejection: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter (CRL) declining to approve its New Drug Application (NDA) for relacorilant, citing insufficient evidence of effectiveness, which led to a 50.42% drop in stock price to $34.80, highlighting significant regulatory risks impacting the company's valuation.
- Stock Price Volatility: Following the FDA's rejection, Corcept's stock plummeted by $35.40, reflecting a pessimistic market sentiment regarding the company's future prospects and severely undermining investor confidence in its drug development capabilities, potentially affecting future financing and R&D initiatives.
- Class Action Initiated: Investors have filed a class action lawsuit due to purchasing Corcept stock between October 31, 2024, and December 30, 2025, alleging that the company made misleading statements and failed to disclose FDA concerns about its clinical development program, which may expose investors to greater losses.
- Legal Implications: Investors must file their motions by April 21, 2026, to be appointed as lead plaintiffs in the class action, indicating that the legal risks faced by the company could further damage its market reputation and shareholder trust, increasing future compliance costs.
See More
Corcept Therapeutics Faces Class Action Lawsuit Over Misleading Statements
- Lawsuit Background: Hagens Berman has filed a class action lawsuit against Corcept Therapeutics and its executives, alleging that they misled investors about the regulatory status of relacorilant, resulting in significant investor losses during the period from October 31, 2024, to December 30, 2025.
- Concealed FDA Warnings: The lawsuit claims that while Corcept publicly asserted that relacorilant was approaching approval, the FDA had warned them multiple times that their clinical data was inadequate, which management allegedly chose to ignore.
- Stock Price Plummet: On December 31, 2025, Corcept's stock price collapsed from $70.20 to $34.80 following the receipt of a Complete Response Letter (CRL) from the FDA, erasing over $3.6 billion in market value and severely impacting investor confidence.
- Legal Consequences and Deadline: Investors must apply to be lead plaintiffs by April 21, 2026, or risk losing their opportunity for recovery, highlighting the potential long-term implications of the lawsuit on the company's future.
See More
Corcept Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications for the Corcept securities class action by April 21, 2026, concerning trades made between October 31, 2024, and December 30, 2025, highlighting investor concerns over potential losses.
- Disclosure Failures: Corcept and its executives are accused of failing to disclose material information during the class period, violating federal securities laws, which severely undermined investor confidence in the company's new drug application.
- Stock Price Plunge: Following the December 31, 2025 disclosure of the FDA's Complete Response Letter regarding its new drug application, Corcept's stock price plummeted by 50.4%, from $70.20 to $34.80, indicating a pessimistic outlook from the market on the company's future prospects.
- Legal Consultation Opportunity: Investors can contact Kahn Swick & Foti to understand their legal rights and how to participate in the lawsuit, reflecting a strong demand among investors for recovering economic losses.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation among affected investors.
- Case Background: The lawsuit alleges that Corcept made false statements regarding the clinical trials supporting the NDA for relacorilant, claiming that the evidence was “powerful support,” while the FDA had raised concerns about its adequacy, resulting in significant investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Navan and Corcept Face Class Action Lawsuits
- Navan IPO Issues: Navan conducted its IPO on October 30, 2025, selling approximately 36.9 million shares at $25 each, but due to undisclosed increases in sales and marketing expenses, its stock plummeted to $9.01 by the time the lawsuit commenced, representing a decline of over 60%, resulting in significant investor losses.
- Lawsuit Deadlines: Navan shareholders must petition to serve as lead plaintiff by April 24, 2026, reflecting investor concerns over the company's transparency and financial health, which could impact future fundraising capabilities.
- Corcept Approval Risks: Corcept's relacorilant faced a Complete Response Letter from the FDA on December 31, 2025, requiring additional evidence of effectiveness, causing its stock price to drop from $70.20 to $34.80, a 50.4% decline, highlighting significant uncertainties in the company's drug development.
- FDA Communication Missteps: During the class period, Corcept claimed smooth communication with the FDA and confidence in its NDA submission, but the FDA's concerns about clinical evidence raised the risk of non-approval, exacerbating investor confidence issues.
See More
